5 completed, 3 recruiting, 2 active not recruiting, 1 not yet recruiting. 5 Phase 2, 2 Phase 1, 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Recruiting 2, Active not recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 4 | 1 | Active not recruiting 1 |
Follow sparsentan: new trials by email Literature Review of sparsentan trials Research Report on sparsentan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria sparsentan, No sparsentan - Proteinuric Renal Disease, Proteinuric Kidney Disease | Phase 1 | Recruiting | Brigham and Women's Hospital | 20 | 2026-07-10 | 2026-07-30 |
| Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy sparsentan - IgA Nephropathy (IgAN) | Not yet recruiting | Waid City Hospital, Zurich | 50 | 2026-06-01 | 2026-04-29 | |
| Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis Sparsentan - Proteinuria, Immunoglobulin A (IgA) Nephropathy | Phase 4 | Active not recruiting | Travere Therapeutics, Inc. | 20 | 2025-10-07 | 2026-06-23 |
| A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN Sparsentan - Immunoglobulin A Nephropathy | Phase 2 | Completed | Travere Therapeutics, Inc. | 48 | 2023-05-19 | 2025-11-20 |
| ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) Sparsentan - ANCA Associated Vasculitis, Cardiovascular Diseases | Phase 2 | Active not recruiting | University of Edinburgh | 32 | 2022-12-08 | 2026-08-26 |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Sparsentan - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | Travere Therapeutics, Inc. | 67 | 2021-08-12 | 2026-05-12 |
| A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy Sparsentan - Immunoglobulin A Nephropathy, Kidney Diseases | Phase 2 | Recruiting | University of Leicester | 24 | 2020-12-10 | 2026-06-03 |
| Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension RE-021, sparsentan - Healthy Subjects | Phase 1 | Completed | Travere Therapeutics, Inc. | 47 | 2020-06-18 | 2022-09-30 |
| A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy sparsentan, irbesartan, Dapagliflozin - Immunoglobulin A Nephropathy | Phase 3 | Completed | Travere Therapeutics, Inc. | 406 | 2018-12-11 | 2026-10-14 |
| Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) sparsentan, Irbesartan - Focal Segmental Glomerulosclerosis | Phase 3 | Completed | Travere Therapeutics, Inc. | 371 | 2018-04-17 | 2026-04-17 |
| Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis RE-021 (Sparsentan), Irbesartan - Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Travere Therapeutics, Inc. | 109 | 2014-03-01 | 2025-05-15 |
Glomerulonephritis, IGA (6) · Glomerulosclerosis, Focal Segmental (5) · Kidney Diseases (3) · Proteinuria (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Autoimmune Diseases (1) · Cardiovascular Diseases (1) · Glomerulonephritis (1) · IgA Vasculitis (1) · Immune System Diseases (1) · Macular dystrophy, corneal type 1 (1) · Neoplasms (1) · Nephritis, Hereditary (1) · Nephrosis, Lipoid (1) · Nephrotic Syndrome (1)
Travere Therapeutics, Inc. (7) · Brigham and Women's Hospital (1) · University of Edinburgh (1) · University of Leicester (1) · Waid City Hospital, Zurich (1)
United States (7) · United Kingdom (6) · Italy (4) · Czechia (3) · Germany (3) · Hong Kong (3) · Poland (3) · Spain (3) · Australia (2) · Belgium (2) · Croatia (2) · Estonia (2) · France (2) · New Zealand (2) · Portugal (2)
Radko Komers, MD, PhD (5) · Chee Kay Cheung, MBChB PhD (1) · Howard Trachtman, M.D. (1) · Neeraj Dhaun (1)
PMID 35224732, PMID 37254256, PMID 40337980, PMID 40938675, PMID 30361325, PMID 36657027, PMID 37015244, PMID 37921461, PMID 37931634, PMID 38299639, PMID 38724717, PMID 38831932, PMID 41428405, PMID 41433094, PMID 42384439
2017 (1), 2018 (1), 2023 (1)